Targeted Proteasome Inhibitor for Therapy of Autoimmune Diseases, API

COOPERATION OPTIONS

LICENSE

FROM 150 MILLION RUR

RESEARCH PARTNERSHIP

FROM 20 MILLION RUR

more detail

ABOUT THE PROJECT

TARGETED PROTEASOME INHIBITOR FOR THERAPY OF AUTOIMMUNE DISEASES, API

A NEW CLASS OF TARGETED PROTEASOME INHIBITORS

There are several classes of proteasome inhibitors on the market. However, these substances act on all types of proteasomes in all cells, resulting in the brake of proteolysis and cell death through apoptosis, which is accompanied by significant side effects of their use. The new inhibitor has greater selectivity for the immunoproteasome and has a greater effect on cells that are “malfunctioning”.

STAGE OF DEVELOPMENT

TARGETED PROTEASOME INHIBITOR FOR THERAPY OF AUTOIMMUNE DISEASES, API

COOPERATION OPTIONS

LICENSE

FROM 150 MILLION RUR

RESEARCH PARTNERSHIP

FROM 20 MILLION RUR

more detail

ABOUT THE PROJECT

TARGETED PROTEASOME INHIBITOR FOR THERAPY OF AUTOIMMUNE DISEASES, API

A NEW CLASS OF TARGETED PROTEASOME INHIBITORS

There are several classes of proteasome inhibitors on the market. However, these substances act on all types of proteasomes in all cells, resulting in the brake of proteolysis and cell death through apoptosis, which is accompanied by significant side effects of their use. The new inhibitor has greater selectivity for the immunoproteasome and has a greater effect on cells that are “malfunctioning”.

STAGE OF DEVELOPMENT

STAGE OF DEVELOPMENT
& RESULTS OF INTELLECTUAL ACTIVITY STATUS


APPLICATION

Treatment of a wide range of autoimmune diseases: multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, psoriasis, scleroderma, primary antiphospholipid antibody syndrome, glomerulonephritis, autoimmune enteropathy, celiac disease and others.

EFFECT

The action of API is based on the method of targeted blocking of the immunoproteasome, which is involved in the inflammatory process. The new approach can significantly mitigate the symptoms of many autoimmune diseases.

BENEFITS

Increased therapeutic effect

REDUCED DOSAGE

REDUCED SIDE EFFECTS DUE TO THE TARGETING NATURE

THE BROAD FIELD OF APPLICATION DUE TO THE PRESENCE OF A TARGET FOR ALMOST ANY AUTOIMMUNE DISEASE 

COOPERATION OPTIONS

Options for project implementation include Intellectual Property license agreement and/or further product development together with investor.
license agreement 

Conclusion of agreements on disposal of exclusive intellectual property rights (license agreements). 

Approximate investment amount: 

• Granting the right to use results of intellectual activity - starting at RUB 150 million RUR

• Royalty 5%

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to bring research to the market launching stage and to organize product manufacturing and sales.

Approximate investment amount: 

Starting at 240 million RUR 

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to reach the further research stage(s) and to sale of the scientific product in the form of sublicensing.

Approximate investment amount:

• Preclinical studies
Starting at 20 million RUR

• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 50 million RUR

• Clinical trials, phase 3
Starting at 50 million RUR

investment partnership agreements

Conclusion of investment partnership agreements for further research stages on the investor basis with the participation of IBCh RAS.

The aim: to obtain a scientific product or "ready to market" product.

Approximate investment amount: 

• Preclinical studies
Starting at 20 million RUR

• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 50 million RUR

• Clinical trials, phase 3
Starting at 50 million RUR

• Start manufacturing
Starting at 20 million RUR

• Promotion activities
Starting at 50 million RUR

MOSCOW GOVERNMENT AWARD


Award of the Moscow Government to Young Scientists (Y2018) in the nomination "Pharmaceuticals, medical equipment and materials" for the development of the first original domestic therapeutic agent for the treatment of multiple sclerosis.

DEVELOPERS

The Shemyakin & Ovchinnikov Institute of bioorganic chemistry (IBCh) of the Russian Academy of Sciences is one of the largest Russian scientific organizations. The Institute is a leader in fundamental and innovative researches on the fields of molecular, structural and cell biology, bioorganic chemistry, biophysics, bioengineering, cell technologies, “in vivo” molecular based bioimaging, genome editing, bioinformatics etc. This multidisciplinary structure allows large-scale research at the interface of sciences, where the most interesting scientific discoveries are born today.

The hallmark of the IBCh RAS is the concentration of efforts and resources on solving the most urgent and complicated problems on the field of life sciences. Talented young people and leading specialists, including Russian and foreign science leaders, Nobel Prize laureates and members of the international advisory council of the Institute are involved in.

HEAD OF THE PROJECT

ALEXEY BELOGUROV 

Dr. of Sc. in Chemistry
Professor, Fundamental Medicine Faculty, Moscow State University
Laureate of the Moscow Government Award for Young Scientists

Deputy Director of IBH RAS
Deputy Head of the NTI Center IBH RAS

Head of the Laboratory of Hormonal Regulation Proteins (IBCh) and the Laboratory of Molecular Biomedicine (NTIC IBCh RAS)

 


publications

Russian scientists have learned to locally suppress inflammation in autoimmune diseases

Found a way to suppress inflammation in autoimmune diseases without reducing immunity

The RSCF Lecture Hall has been held at the International Youth Scientific Forum "Lomonosov-2019"


CONTACT us

get in touch

On cooperation issues please contact the head of NTI Center project department
Sergey Semenov
E-mail consortium@cnti-ibch.ru
address 16/10, Miklukho-Maklaya St, Moscow, Russian Federation, 117997
All products and services of NTI Center IBHh RAS
view more